Inhaled liposomal amikacin

Expert Review of Respiratory Medicine

Volumn 8, Issue 4, 2014, Pages 401-409

  Waters, Valerie ^a   Ratjen, Felix ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Amikacin; Clinical trial; Cystic fibrosis; Inhalation; Pseudomonas

Indexed keywords

AMIKACIN; ARIKACE; TOBRAMYCIN; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT;

ANTIBIOTIC THERAPY; ARTICLE; CYSTIC FIBROSIS LUNG INFECTION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FORCED EXPIRATORY VOLUME; HUMAN; LIPOSOMAL DELIVERY; LUNG FIBROSIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; COMPLICATION; CYSTIC FIBROSIS; INHALATIONAL DRUG ADMINISTRATION; PSEUDOMONAS INFECTIONS; RESPIRATORY TRACT INFECTIONS; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; AMIKACIN; ANTI-BACTERIAL AGENTS; CYSTIC FIBROSIS; HUMANS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RESPIRATORY TRACT INFECTIONS; TREATMENT OUTCOME;

EID: 84904326573     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/17476348.2014.918507     Document Type: Article

References (56)

1. Mandell GL BJ, Dolin R. Principles and practice of infectious diseases. 6th edition. Elsevier Churchill Livingstone; Philadelphia, Pennsylvania, USA: 2010
2. Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003;168(8): 918-51
3. Patient Data Registry Report [database on the Internet]. CF Foundation; Bethesda, MD, USA: 2011
4. Waters V, Ratjen F. Multidrug-resistant organisms in cystic fibrosis: management and infection-control issues. Expert Rev Anti Infect Ther 2006;4(5): 807-19
5. Kosorok MR, Zeng L, West SE, et al. Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition. Pediatr Pulmonol 2001;32(4): 277-87
6. Henry RL, Mellis CM, Petrovic L. Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis. Pediatr Pulmonol 1992;12(3): 158-61
7. Pamukcu A, Bush A, Buchdahl R. Effects of Pseudomonas aeruginosa colonization on lung function and anthropometric variables in children with cystic fibrosis. Pediatr Pulmonol 1995;19(1): 10-15
8. Cystic Fibrosis Canada. Canadian Patient Data Registry Report. Toronto, Canada: 2010
9. Waters V, Yau Y, Prasad S, et al. Stenotrophomonas maltophilia in cystic fibrosis: serologic response and effect on lung disease. Am J Respir Crit Care Med 2011;183(5): 635-40
10. Waters V, Atenafu EG, Lu A, et al. Chronic Stenotrophomonas maltophilia infection and mortality or lung transplantation in cystic fibrosis patients. J Cyst Fibros 2013;12(5): 482-6
11. Corey M, Farewell V. Determinants of mortality from cystic fibrosis in Canada, 1970-1989. Am J Epidemiol 1996;143(10): 1007-17
12. Tablan OC, Chorba TL, Schidlow DV, et al. Pseudomonas cepacia colonization in patients with cystic fibrosis: risk factors and clinical outcome. J Pediatr 1985;107(3): 382-7
13. Ramsey BW, Dorkin HL, Eisenberg JD, et al. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N Engl J Med 1993;328(24): 1740-6
14. Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 1999;340(1): 23-30
15. Gibson RL, Emerson J, McNamara S, et al. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am J Respir Crit Care Med 2003; 167(6): 841-9
16. MacLusky IB, Gold R, Corey M, Levison H. Long-term effects of inhaled tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa. Pediatr Pulmonol 1989;7(1): 42-8
17. Steinkamp G, Tummler B, Gappa M, et al. Long-term tobramycin aerosol therapy in cystic fibrosis. Pediatr Pulmonol 1989;6(2): 91-8
18. Parkins MD, Elborn JS. Tobramycin Inhalation Powder: a novel drug delivery system for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis. Expert Rev Respir Med 2011;5(5): 609-22
19. Oermann CM, Retsch-Bogart GZ, Quittner AL, et al. An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis. Pediatr Pulmonol 2010;45(11): 1121-34
20. Konstan MW, Flume PA, Kappler M, et al. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: the EAGER trial. J Cyst Fibros 2011;10(1): 54-61
21. Schuster A, Haliburn C, Doring G, Goldman MH. Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study. Thorax 2013;68(4): 344-50
22. Lagace J, Dubreuil M, Montplaisir S. Liposome-encapsulated antibiotics: preparation, drug release and antimicrobial activity against Pseudomonas aeruginosa. J Microencapsul 1991;8(1): 53-61
23. Omri A, Beaulac C, Bouhajib M, et al. Pulmonary retention of free and liposome-encapsulated tobramycin after intratracheal administration in uninfected rats and rats infected with Pseudomonas aeruginosa. Antimicrob Agents Chemother 1994;38(5): 1090-5
24. Beaulac C, Clement-Major S, Hawari J, Lagace J. Eradication of mucoid Pseudomonas aeruginosa with fluid liposome-encapsulated tobramycin in an animal model of chronic pulmonary infection. Antimicrob Agents Chemother 1996;40(3): 665-9
25. Sachetelli S, Khalil H, Chen T, et al. Demonstration of a fusion mechanism between a fluid bactericidal liposomal formulation and bacterial cells. Biochim Biophys Acta 2000;1463(2): 254-66
26. Beaulac C, Sachetelli S, Lagace J. In-vitro bactericidal efficacy of sub-MIC concentrations of liposome-encapsulated antibiotic against gram-negative and gram-positive bacteria. J Antimicrob Chemother 1998;41(1): 35-41
27. Halwani M, Mugabe C, Azghani AO, et al. Bactericidal efficacy of liposomal aminoglycosides against Burkholderia cenocepacia. J Antimicrob Chemother 2007; 60(4): 760-9
28. Clancy J. Clinical Trials of Lipid-Associated Aerosolized Amikacin: the Arikace Story. Pediatr Pulmonol 2009;44: 109-212
29. Li Z, Zhang Y, Wurtz W, et al. Characterization of nebulized liposomal amikacin (Arikace) as a function of droplet size. J Aerosol Med Pulm Drug Deliv 2008; 21(3): 245-54
30. Konstan MW, Geller DE, Minic P, et al. Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: the EVOLVE trial. Pediatr Pulmonol 2011; 46(3): 230-8
31. ClinicalTrials.gov. Available from: http://clinicaltrials.gov/ct2/show/ NCT01315691
32. Meers P, Neville M, Malinin V, et al. Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections. J Antimicrob Chemother 2008;61(4): 859-68
33. Prince AS. Biofilms, antimicrobial resistance, and airway infection. N Engl J Med 2002;347(14): 1110-11
34. Chinoy MR, Fisher AB, Shuman H. Confocal imaging of time-dependent internalization and localization of NBD-PC in intact rat lungs. Am J Physiol 1994; 266(6 Pt 1):L713-21
35. ME Neville SL, Artis C, Dadey, E, Gupta, R. Functionality of foamy alveolar macrophages after inhalation of aerosolized liposomal amikacin (Arikace). Pediatr Pulmonol 2009;44: 109-212
36. Weers J, Metzheiser B, Taylor G, et al. A gamma scintigraphy study to investigate lung deposition and clearance of inhaled amikacin-loaded liposomes in healthy male volunteers. J Aerosol Med Pulm Drug Deliv 2009;22(2): 131-8
37. Okusanya OO, Bhavnani SM, Hammel J, et al. Pharmacokinetic and pharmacodynamic evaluation of liposomal amikacin for inhalation in cystic fibrosis patients with chronic Pseudomonal infection. Antimicrob Agents Chemother 2009;53(9): 3847-54
38. Clancy JP, Dupont L, Konstan MW, et al. Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection. Thorax 2013;68(9): 818-25
39. Bilton D, Pressler T, Isabelle F, et al. Phase 3 efficacy and safety data from randomized, multicenter study of liposomal amikacin for inhalation (Arikace) compared with TOBI in cystic fibrosis patients with chronic infection due to Pseudomonas aeruginosa. North American Cystic Fibrosis Conference; Salt Lake City, Utah. Pediatr Pulmonol 2013(Suppl 36): 290
40. Esther CR Jr, Henry MM, Molina PL, Leigh MW. Nontuberculous mycobacterial infection in young children with cystic fibrosis. Pediatr Pulmonol 2005;40(1): 39-44
41. Fauroux B, Delaisi B, Clement A, et al. Mycobacterial lung disease in cystic fibrosis: a prospective study. Pediatr Infect Dis J 1997;16(4): 354-8
42. Levy I, Grisaru-Soen G, Lerner-Geva L, et al. Multicenter cross-sectional study of nontuberculous mycobacterial infections among cystic fibrosis patients, Israel. Emerg Infect Dis 2008;14(3): 378-84
43. Sermet-Gaudelus I, Le Bourgeois M, Pierre-Audigier C, et al. Mycobacterium abscessus and children with cystic fibrosis. Emerg Infect Dis 2003;9(12): 1587-91
44. Olivier KN, Weber DJ, Lee JH, et al. Nontuberculous mycobacteria. II: nested-cohort study of impact on cystic fibrosis lung disease. Am J Respir Crit Care Med 2003;167(6): 835-40
45. Olivier KN, Weber DJ, Wallace RJ Jr, et al. Nontuberculous mycobacteria. I: multicenter prevalence study in cystic fibrosis. Am J Respir Crit Care Med 2003;167(6): 828-34
46. Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007;175(4): 367-416
47. Aitken ML, Limaye A, Pottinger P, et al. Respiratory Outbreak of Mycobacterium abscessus Subspecies massiliense in a Lung Transplant and Cystic Fibrosis Center. Am J Respir Crit Care Med 2012;185(2): 231-2
48. Gayathri R, Therese KL, Deepa P, et al. Antibiotic susceptibility pattern of rapidly growing mycobacteria. J Postgrad Med 2010;56(2): 76-8
49. Park S, Kim S, Park EM, et al. In vitro antimicrobial susceptibility of Mycobacterium abscessus in Korea. J Korean Med Sci 2008;23(1): 49-52
50. Yang SC, Hsueh PR, Lai HC, et al. High prevalence of antimicrobial resistance in rapidly growing mycobacteria in Taiwan. Antimicrob Agents Chemother 2003;47(6): 1958-62
51. Shen GH, Wu BD, Wu KM, Chen JH. In Vitro activities of isepamicin, other aminoglycosides, and capreomycin against clinical isolates of rapidly growing mycobacteria in Taiwan. Antimicrob Agents Chemother 2007;51(5): 1849-51
52. Davis KK, Kao PN, Jacobs SS, Ruoss SJ. Aerosolized amikacin for treatment of pulmonary Mycobacterium avium infections: an observational case series. BMC Pulm Med 2007;7: 2
53. Colin AA. Eradication of Mycobacterium abscessus in a chronically infected patient with cystic fibrosis. Pediatr Pulmonol 2000; 30(3): 267-8
54. ClinicalTrials.gov. Available from: http://clinicaltrials.gov/ct2/show/ NCT01315236
55. Chastre J, Fagon JY. Ventilator-associated pneumonia. Am J Respir Crit Care Med 2002;165(7): 867-903
56. Niederman MS, Chastre J, Corkery K, et al. BAY41-6551 achieves bactericidal tracheal aspirate amikacin concentrations in mechanically ventilated patients with Gram-negative pneumonia. Intensive Care Med 2012;38(2): 263-71